InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

InspireMD Stock Down 2.2 %

Shares of InspireMD stock opened at $2.27 on Tuesday. The firm has a market cap of $53.25 million, a PE ratio of -2.10 and a beta of 0.84. The business’s fifty day moving average is $2.49 and its two-hundred day moving average is $2.74. InspireMD has a fifty-two week low of $0.96 and a fifty-two week high of $3.85.

InspireMD (NYSE:NSPR) last released its quarterly earnings data on Wednesday, March 6th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 55.71% and a negative net margin of 320.97%. The business had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.65 million. During the same period in the prior year, the firm posted ($0.60) EPS. Equities research analysts anticipate that InspireMD will post -0.61 EPS for the current year.

Hedge Funds Weigh In On InspireMD

Large investors have recently modified their holdings of the stock. Nantahala Capital Management LLC raised its holdings in shares of InspireMD by 16.9% during the fourth quarter. Nantahala Capital Management LLC now owns 2,066,456 shares of the company’s stock valued at $5,807,000 after buying an additional 298,406 shares during the last quarter. Marshall Wace LLP acquired a new position in InspireMD in the second quarter worth approximately $4,670,000. Northern Trust Corp acquired a new position in InspireMD in the fourth quarter worth approximately $80,000. Avestar Capital LLC acquired a new position in InspireMD in the third quarter worth approximately $65,000. Finally, Renaissance Technologies LLC acquired a new position in InspireMD in the second quarter worth approximately $36,000. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions.